Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2

References

• Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737–3743
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Myers CE. Prospective randomized trial of intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985; 12: 101–111
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Radacic M, Khalil AA, Horsman MR, Overgaard J. Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature. Acta Oncol 1992; 31: 347–351
   PubMed Web of Science ®Google Scholar
• Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006; 66: 5419–5426
   PubMed Web of Science ®Google Scholar
• Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72: 937–940
   PubMed Web of Science ®Google Scholar
• Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989; 27: 621–627
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380–3384
   PubMed Web of Science ®Google Scholar
• Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, Smals O, Gonzalez–Gonzalez D, McVie JG. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27: 472–477
   PubMed Web of Science ®Google Scholar
• Basic I, Varga E. Immunogenicity of mammary carcinoma and a fibrosarcoma of CBA mice. Period Biol 1979; 81: 335–337
   Web of Science ®Google Scholar
• Oršolić N, Bašić I. Immunomodulation by water-soluble derivative of propolis (WSDP) a factor of antitumor reactivity. J Ethnopharmacol 2003; 84: 265–273
   PubMed Web of Science ®Google Scholar
• Plowman J, Dykes DJ, Hollingshead M. Anticancer drug development guide: Preclinical screening, clinical trials, and approval. Humana, Totowa, NJ 1995; 101
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–465
   Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748
   PubMed Web of Science ®Google Scholar
• Farrar WL, Johnson HM, Farrar JJ. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 1981; 126: 1120–1125
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–1414
   PubMed Web of Science ®Google Scholar
• Hadden JW. Recent advances in the preclinical and clinical immunopharmcology of interleukin-2: Emphasis on IL-2 as an immunorestorative agent. Cancer Detect Prev 1988; 12: 537–552
   PubMedGoogle Scholar
• Oršolić N, Horvat Knežević A, Šver L, Terzić S, Bašić I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol 2004; 94: 307–315
   PubMed Web of Science ®Google Scholar
• Ben Salah-Abbès J, Abbès S, Houas Z, Abdel-Wahhab MA, Oueslati R. Zearalenone induces immunotoxicity in mice: Possible protective effects of radish extract (Raphanus sativus). J Pharm Pharmacol 2008; 60(6)761–770
   PubMed Web of Science ®Google Scholar
• Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Jezzi M, De Giovanni C, Lollini PL. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007; 67(22)11037–11044, 12034
   PubMedGoogle Scholar
• Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003; 3: 1105–1119
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 2005; 32: S68–73
   Google Scholar
• Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 1998; 4: 121–140
   Google Scholar
• Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, Guillet JL, Madelenat P. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 2001; 22: 40–45
   PubMed Web of Science ®Google Scholar
• de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79: 46–61
   PubMed Web of Science ®Google Scholar
• Marmor JB. Interactions of hyperthermia and chemotherapy in animals. Cancer Res 1979; 39: 2269–2276
   PubMed Web of Science ®Google Scholar
• Fu QG, Meng FD, Shen XD, Guo RX. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol 2002; 8(6)1019–1022
   Web of Science ®Google Scholar
• Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, Palmeri S, Lannelli A, Mancarella S, Tafuto S, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13: 866–873
   Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059–2069
   PubMed Web of Science ®Google Scholar
• Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993; 113: 631–636
   Google Scholar
• Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol 1989; 16: 230–253
   PubMed Web of Science ®Google Scholar
• Mihich E. Historical overview of biologic response modifiers. Cancer Invest 2000; 18: 456–466
   PubMed Web of Science ®Google Scholar
• Newman RA, Dogramatzis D, Benvenuto JA, Trevino M, Stephens LC, Wondergem J, Strebel R, Baba H, Bull JM. Effect of whole-body hyperthermia on pharmacokinetics and tissue distribution of doxorubicin. Int J Hyperthermia 1992; 8(1)79–85
   PubMed Web of Science ®Google Scholar
• Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Research 1976; 36: 2891–2895
   PubMed Web of Science ®Google Scholar
• Ehrke MJ, Verstovsek S, Zaleskis G, Ho RL, Ujhazy P, Maccubbin DL, Mihich E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother 1996; 42: 221–230
   PubMed Web of Science ®Google Scholar
• Nomura E, Niki M, Fujii K, Shinohara H, Nishiguchi K, Sonoda T, Tanigawa N. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001; 4: 75–82
   Google Scholar
• McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27: 65–73
   PubMed Web of Science ®Google Scholar